Implantable amyloid hydrogels for promoting stem cell differentiation to neurons

Das, Subhadeep; Zhou, Kun; Ghosh, Dhiman; Jha, Narendra Nath; Singh, Pradeep K.; Jacob, Reeba S.; Bernard, Claude Charles Andre; Finkelstein, David I.; Forsythe, John S.; Maji, Somnath

doi:10.1038/am.2016.116

Cited by 68 publications

(88 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there are several ongoing studies investigating the regulatory and signalling pathways that are instrumental in dictating how neuronal differentiation occurs in 3D matrices in vitro, attempts to incorporate stem cell-encapsulated hydrogels in animal models of neurological disorders have yielded some promising results. An amyloid-inspired peptide hydrogel that uses α-synuclein protein to form a nano-fibrous network was found to promote differentiation of mesenchymal stem cells into a neuronal lineage when implanted into the substantia nigra and striatal regions of the basal ganglia in animal models of Parkinson's disease [85].…”

Section: Cells Encapsulated In Hydrogelsmentioning

confidence: 99%

Hydrogel systems and their role in neural tissue engineering

Madhusudanan

Raju

Shankarappa

2020

J. R. Soc. Interface.

131

View full text Add to dashboard Cite

Neural tissue engineering (NTE) is a rapidly progressing field that promises to address several serious neurological conditions that are currently difficult to treat. Selecting the right scaffolding material to promote neural and non-neural cell differentiation as well as axonal growth is essential for the overall design strategy for NTE. Among the varieties of scaffolds, hydrogels have proved to be excellent candidates for culturing and differentiating cells of neural origin. Considering the intrinsic resistance of the nervous system against regeneration, hydrogels have been abundantly used in applications that involve the release of neurotrophic factors, antagonists of neural growth inhibitors and other neural growth-promoting agents. Recent developments in the field include the utilization of encapsulating hydrogels in neural cell therapy for providing localized trophic support and shielding neural cells from immune activity. In this review, we categorize and discuss the various hydrogel-based strategies that have been examined for neural-specific applications and also highlight their strengths and weaknesses. We also discuss future prospects and challenges ahead for the utilization of hydrogels in NTE.

show abstract

Section: Cells Encapsulated In Hydrogelsmentioning

confidence: 99%

Hydrogel systems and their role in neural tissue engineering

Madhusudanan

Raju

Shankarappa

2020

J. R. Soc. Interface.

131

View full text Add to dashboard Cite

show abstract

“…Moreover, the delivery of GDNF containing microspheres in an injectable fibrin hydrogel enhanced the length of GDNF release in situ to 2 weeks compared to 3 days with "free" GDNF (Wood et al, 2013). Similarly, hydrogels have also been successfully used to enhance cellular delivery (Aguado, Mulyasasmita, Su, Lampe, & Heilshorn, 2012;Ballios et al, 2015;Das et al, 2016;Freudenberg et al, 2009). Three recent studies have highlighted the potential of injectable hydrogels to improve dopaminergic cell replacement strategies.…”

Section: F I G U R E 1 Therapeutic Concept Of Biomaterials For Brain mentioning

confidence: 99%

Primary tissue for cellular brain repair in Parkinson's disease: Promise, problems and the potential of biomaterials

Moriarty

Parish

Dowd

2018

Eur J of Neuroscience

View full text Add to dashboard Cite

The dopamine precursor, levodopa, remains the "gold standard" treatment for Parkinson's disease, and, although it provides superlative efficacy in the early stages of the disease, its long-term use is limited by the development of severe motor side effects and a significant abating of therapeutic efficacy. Therefore, there remains a major unmet clinical need for the development of effective neuroprotective, neurorestorative or neuroreparatory therapies for this condition. The relatively selective loss of dopaminergic neurons from the nigrostriatal pathway makes Parkinson's disease an ideal candidate for reparative cell therapies, wherein the dopaminergic neurons that are lost in the condition are replaced through direct cell transplantation into the brain. To date, this approach has been developed, validated and clinically assessed using dopamine neuron-rich foetal ventral mesencephalon grafts which have been shown to survive and reinnervate the denervated brain after transplantation, and to restore motor function. However, despite long-term symptomatic relief in some patients, significant limitations, including poor graft survival and the impact this has on the number of foetal donors required, have prevented this therapy being more widely adopted as a restorative approach for Parkinson's disease. Injectable biomaterial scaffolds have the potential to improve the delivery, engraftment and survival of these grafts in the brain through provision of a supportive microenvironment for cell adhesion, growth and immune shielding. This article will briefly review the development of primary cell therapies for brain repair in Parkinson's disease and will consider the emerging literature which highlights the potential of using injectable biomaterial hydrogels in this context.

show abstract

“…Various biomaterials are the subject of ongoing research to develop injectable hydrogels. [2][3][4][5][6][7] An ionized biomaterial that bears cationic or anionic charges can exist in solution in a homogeneous state. 8 However, if this biomaterial solution is mixed with another that possesses an opposite charge, electrostatic interactions can result in the formation of electrostatic cross-linking between the biomaterials.…”

Section: Introductionmentioning

confidence: 99%

“…Accordingly, the objectives of this work were as follows: (1) to evaluate whether the prepared injectable, electrostatic, cross-linkable CMC and CHI formulation acts as a suitable Cur depot in vivo and (2) to determine whether the electrostatic, cross-linked CCH with Cur-M can produce synergistic tumor regression. Resolving these issues will help develop an efficient strategy for an injectable, electrostatic, crosslinkable Cur-M-loaded CCH formulation.…”

Section: Introductionmentioning

confidence: 99%

An intratumoral injectable, electrostatic, cross-linkable curcumin depot and synergistic enhancement of anticancer activity

et al. 2017

View full text Add to dashboard Cite

In this study, we describe an intratumoral injectable, electrostatic, cross-linkable curcumin (Cur) drug depot to enhance anticancer activity. The key concept in this work was the preparation of an electrostatic, cross-linked carboxymethyl cellulose (CMC) and chitosan (CHI) hydrogel containing Cur-loaded microcapsules (Cur-M). The CMC and CHI solutions existed as a liquid before mixing and formed a CMC and CHI (CCH) hydrogel as a drug depot after mixing via electrostatic interactions between the anionic CMC and cationic CHI. Compared with the individual CMC and CHI solutions, the electrostatic, cross-linked CCH depot persisted in vivo for an extended period. The prepared Cur-M was easily mixed with the CMC and CHI solutions. Cur-M/CMC and Cur-;M/CHI solutions easily formed Cur-M-loaded CCH depots after simple mixing. The in vitro and in vivo Cur-M-loaded CCH depot was designed with Cur-M dispersed inside an outer shell of electrostatically cross-linked CCH. The Cur-M-loaded CCH depot produced greater inhibition of tumor growth than did Cur-M, whereas single and repeated injections of free Cur had the weakest inhibitory effects. The results of this study indicate that the electrostatic, cross-linked, Cur-M-loaded CCH depot described in this study can synergistically enhance anticancer activity in chemotherapeutic delivery systems. Preparation of Cur-MCur-M was prepared using a monoaxial one-nozzle atomizer (Sono-Tek Crop, Milton, NY, USA). The typical preparation of Cur-M was achieved as follows: PLGA and Cur were dissolved in ethyl acetate and methanol, respectively. The concentrations of PLGA and Cur were 3% and 5% w/v, respectively. The mixtures of PLGA and Cur were fed into the ultrasonic atomizer at flow rates of 4 ml min − 1 . Microdroplets were produced by atomizing the mixed solutions of PLGA and Cur for~5 s at a vibration frequency of 3 W per 60 kHz and the microdroplets were then immediately collected in a 0.5% w/v poly(vinyl alcohol) solution for 2 min. The distance between the atomizer head and the aqueous poly(vinyl alcohol) solution was 1 cm, and the stirring speed of the poly(vinyl alcohol) solution was 1000 r.p.m. The resulting mixtures were gently stirred for 2 h to allow solidification of the microcapsules and were then filtered and washed with distilled water. The Cur-M was frozen at − 75°C, followed by freeze-drying over 4 days. The morphology of Cur-M was confirmed using an optical microscope (Carl Zeiss MicroimagingThe encapsulation efficiency of Cur was determined using acetonitrile and DW. Cur-M (4 mg) was placed into a test tube and 0.6 ml acetonitrile was added to Injectable, electrostatic, cross-linkable curcumin SH Park et al

show abstract

Implantable amyloid hydrogels for promoting stem cell differentiation to neurons

Cited by 68 publications

References 57 publications

Hydrogel systems and their role in neural tissue engineering

Hydrogel systems and their role in neural tissue engineering

Primary tissue for cellular brain repair in Parkinson's disease: Promise, problems and the potential of biomaterials

An intratumoral injectable, electrostatic, cross-linkable curcumin depot and synergistic enhancement of anticancer activity

Contact Info

Product

Resources

About